Overview
Avi Maimon practices practicing medicine in Rehovot, Israel.
His clinical expertise encompasses Triple-Negative Breast Cancer, Lung Metastases, and Secondary Peritonitis.
He is actively involved in clinical research, co-authoring 14 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Avi Maimon
Is Avi Maimon a top-rated expert for Triple-Negative Breast Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Avi Maimon is classified as an Experienced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Avi Maimon participate in research or clinical trials?
Yes. Avi Maimon has published 14 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Avi Maimon's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Lung MetastasesMr. Maimon isExperienced. Learn about Lung Metastases.
- Secondary PeritonitisMr. Maimon isExperienced. Learn about Secondary Peritonitis.
- Triple-Negative Breast CancerMr. Maimon isExperienced. Learn about Triple-Negative Breast Cancer.